The world’s largest pharmaceutical companies mostly steered clear of billion-dollar acquisitions in the early months of this year, perhaps indicating how a tumultuous U.S. political environment has led would-be buyers to view bigger deals as too risky for the time being. Two acquisitions worth $1 billion up front or more — that of psychiatry drugmaker Intra-Cellular Therapies and cancer specialist IDRx — were announced between January and March, according to BioPharma Dive data on the industry’s more sizable transactions. By comparison, six billion-dollar-plus deals were inked during the same three-month period in 2024, though this year’s tally is not much lower than the average seen across the starts of the last five years.
Read the full article: M&A Recap: Big Pharma Starts the Year Mostly Avoiding Billion-Dollar Deals //
Source: https://www.biopharmadive.com/news/pharma-biotech-dealmaking-first-quarter-2025-size/744410/